Home > News & Events > Press Releases  
Press Releases
Metabolex Names O’Mara, Petty to Executive Posts
Hayward, Calif., (November 29, 2006): Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has promoted Patrick J. O’Mara to vice president for business development and hired Diana Petty as the company’s vice president for human resources and administration.
“We are thrilled to have these two seasoned industry veterans as part of our executive team. Both of them will play a crucial role as we develop our business by expanding our pipeline and our staff,” said President and Chief Executive Officer Harold Van Wart, Ph.D. “Pat and Diana will bring key experience to their new positions – Pat from his 15 years at Metabolex, Diana from her work both within large pharmaceutical companies and as the owner of a successful consulting business.”
O’Mara joined Metabolex in 1991 and has served the company in a variety of operational and business development positions, most recently as senior director of business development. He has played a key role in a wide variety of partnerships, collaborations and agreements, including management of the company’s intellectual property portfolio.
Petty comes to the company after more than 25 years in a variety of human resources and executive management experience. She has worked for 3M and SmithKline Corp. and spent 18 years as the owner and manager of The Leading Source, a consulting business focused on assisting companies in making the most of their human capital.
About Metabolex
Metabolex is a privately held biotechnology company dedicated to the discovery and development of novel therapeutics to transform the treatment of diabetes and related metabolic disorders. Metabolex has drawn on its deep understanding of diabetes to create the largest database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company’s clinical program is focused on developing next-generation insulin sensitizers that lower blood glucose without the serious safety and tolerability issues associated with currently marketed products.
For additional information about Metabolex and its development pipeline, visit www.metabolex.com.
   
Contact: Media:
Mark Bagnall
Metabolex
(510) 293-8800
mbagnall@metabolex.com
 Brian Reid
WeissComm Partners
(703) 402-3626
breid@weisscommpartners.com